ICICI Prudential Asset Management Co Ltd Has $543,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

ICICI Prudential Asset Management Co Ltd boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 18.4% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,074 shares of the company’s stock after buying an additional 167 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in IDEXX Laboratories were worth $543,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Crewe Advisors LLC acquired a new stake in IDEXX Laboratories in the 1st quarter valued at approximately $26,000. Ridgewood Investments LLC bought a new position in shares of IDEXX Laboratories during the 2nd quarter worth approximately $27,000. Institutional & Family Asset Management LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $28,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC lifted its position in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on IDXX. Barclays lowered their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating on the stock in a research note on Monday, November 4th. Stifel Nicolaus decreased their price objective on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a report on Thursday, October 10th. BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 target price on the stock. Piper Sandler restated a “neutral” rating and issued a $435.00 price target (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $429.82 on Thursday. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $35.20 billion, a P/E ratio of 41.45, a P/E/G ratio of 3.72 and a beta of 1.36. IDEXX Laboratories, Inc. has a 12 month low of $404.74 and a 12 month high of $583.39. The stock has a 50 day moving average of $471.09 and a 200-day moving average of $484.18.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating the consensus estimate of $2.69 by $0.11. The firm had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the company earned $2.53 earnings per share. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.